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The Usher syndrome (USH) is the most frequent cause of
inherited combined deaf-blindness. The ciliopathy is clini-
cally and genetically heterogeneous, assigned to three clini-
cal USH types of which the most severe type is USH1. The
USH1C gene encodes the PDZ containing scaffold protein
harmonin which is expressed in form of numerous alterna-
tively spliced variants. Hamonin binds directly to all USH1/
2 proteins and is a key organizer of USH protein networks
in photoreceptor cells. So far no effective treatment for the
ophthalmic component of USH exists. Translational read-
through was introduced as an innovative therapy option for
several non-ocular diseases caused by nonsense mutations
leading to a premature termination stop. Here we compare
the potential of translational read-through inducing drugs
(TRIDs), namely PTC124 (currently in clinical phase-II for
non-ocular diseases) as well as the designer aminoglycoside
NB30 and NB54 as a treatment option for patients carrying
a nonsense mutation in the USH1C gene causing USH1.
We examined read-through in cell culture, retinal cultures
and in vivo in murine retinas. Restoration of the harmonin
function was tested by GST pull-downs and actin filament
bundling. The TRIDs recovered functional harmonin
protein and showed an excellent biocompatibility in retinal
cultures with read-through vs. toxicity evidently superior
for NB54 and PTC124. In vivo administration of NB54 and
PTC124 to mice induced recovery of full-length harmonin.
The high biocompatibility combined with the sustained
read-through efficacies of these novel drugs emphasizes the
potential of TRIDs in treating nonsense mutations in USH
as well as in other ciliopathies.
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